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ABSTRACT
Clinical outcome of pancreatic ductal adenocarcinoma (PDAC) has not been 
improved in the last three decades due to the lack of effective molecular-targeted 
drugs. To identify a novel therapeutic target for PDAC, we have performed genome-
wide anamysis and found that Homo sapiens chromosome 16 open reading frame 
74 (C16orf74) was up-regulated in the vast majority of PDAC. Overexpression of 
C16orf74 protein detected by immunohistochemical analysis was an independent 
prognostic factor for patients with PDAC. The knockdown of endogenous C16orf74 
expression in the PDAC cell lines KLM-1 and PK-59 by vector-based small hairpin-RNA 
(shRNA) drastically attenuated the growth of those cells, whereas ectopic C16orf74 
overexpression in HEK293T and NIH3T3 cells promoted cell growth and invasion, 
respectively. More importantly, the endogenous threonine 44 (T44)-phosphorylated 
form of C16orf74 interacted with the protein phosphatase 3 catalytic subunit alpha 
(PPP3CA) via the PDIIIT sequence in the PPP3CA-binding motif within the middle 
portion of C16orf74 in PDAC cells. The overexpression of mutants of C16orf74 lacking 
the PDIIIT sequence or T44 phosphorylation resulted in the suppression of invasive 
activity compared with wild-type C16orf74, indicating that their interaction should 
be indispensable for PDAC cell invasion. These results suggest that C16orf74 plays 
an important role for PDAC invasion and proliferation, and is a promising target for 
a specific treatment for patients with PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) reveals 
worse prognosis than any other types of malignant tumor. 
The incidence of PDAC is increasing by 1.2% per year, 
and an estimated 53,070 new cases of pancreatic cancer 
were expected to occurred in the US in 2016 [1]. Only 
surgical resection offers a potential cure, but surgical 
resection is possible in only approximately 20% of patients 
with PDAC. The poor prognosis of this malignancy is 
probably due to two major reasons, the difficulty of early 
diagnosis and the generally poor response to current 
therapies, with a 5-year survival rate of 7% [1]. Systemic 
chemotherapy is the standard treatment for patients with 
metastatic PDAC; however, the median overall survival 
is only 11.1 months with FOLFIRINOX (a combination 
of oxaliplatin, irinotecan, fluorouracil, and leucovorin), 
8.5 months with gemcitabine plus nab-paclitaxel, 
and 6.24 months with gemcitabine plus erlotinib (an 
epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor) [2-4]. In combination chemotherapy, such as 
FOLFIRINOX, side effects including hematological 
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toxicity, febrile neutropenia, sensory neuropathy, and 
gastrointestinal toxicity are higher than for single-agent 
gemcitabine; therefore, guidelines recommend that 
FOLFIRINOX be used in patients ≤75 years of age, with 
a good performance status of 0 or 1 and a level of bilirubin 
≤1.5 ULN [5]. 
Molecular-targeted therapies, such as receptor 
tyrosine kinase inhibitors, have been developed for 
PDAC, and gemcitabine plus erlotinib therapy has been 
established. However, these drugs have failed to achieve 
significant improvement (only 2 weeks extension in 
median overall survival compared with single-agent 
gemcitabine) against PDAC [4]. Moreover, there is no 
evidence supporting the use of any other molecular-
targeted therapies in PDAC, including cetuximab (a 
monoclonal antibody targeting epidermal growth factor 
receptor), bevacizumab (a monoclonal antibody targeting 
vascular endothelial growth factor A) or other inhibitors 
[6, 7]. 
Hence, the development of new effective therapies 
based on the identification of PDAC-specific molecular 
targets is urgently needed. We determined detailed 
expression profiles of PDACs using a genome-wide 
cDNA microarray containing approximately 27,000 
genes, in combination with laser microdissection to 
obtain pure populations of cancer cells [8], and identified 
and characterized a novel gene termed C16orf74 that is 
frequently over-expressed in pancreatic cancer specimens. 
The C16orf74 has been reported as Homo sapiens 
chromosome 16 open reading frame 74 (NM_206967.2) 
and is located on chromosome 16q24.1. This gene was 
shown to be associated with tumor necrosis factor (TNF)-
alpha as well as hypoxic condition [9-11]. Moreover, 
several reports have indicated that C16orf74 expression 
is a potential prognostic factor in several types of cancer 
[10, 12-15], but the pathophysiological functions of the 
C16orf74 gene in PDAC cells have not been elucidated. 
In this report, we demonstrate that the C16orf74 gene 
product interacts with the protein phosphatase 3 catalytic 
subunit alpha (PPP3CA) and is indispensable for invasion 
and proliferation of PDAC cells. Accordingly, we suggest 
that C16orf74 is a potential therapeutic target for the 
development of anticancer drugs for the treatment of 
PDAC.
RESULTS
Identification of C16orf74 as an up-regulated gene 
in pancreatic cancer cells
We verified by semi-quantitative RT-PCR that 
C16orf74 was up-regulated in 10 of 12 pancreatic cancer 
specimens compared with normal pancreatic ducts, and 
was up-regulated in capan-1, capan-2 pancreatic cancer 
cell lines compared with normal pancreatic ducts, although 
it was observed a weak band in normal duct cells. (Figure 
1A). Subsequent northern blot analysis using a C16orf74 
cDNA fragment confirmed the overexpression of the 
approximately 1-kb transcript in Capan-1, Miapaca-2 
and Aspc-1 cells. C16orf74 was not expressed in normal 
human organs including the brain, lung, liver, kidney, 
placenta, bone marrow and testis (Figure 1B). 
Because the EST sequence of the C16orf74 gene 
in the National Center for Biotechnology Information 
(NCBI) database (Accession: BE875115; 586bp) is 
smaller than the approximately 1-kb transcript shown 
in Figure 1B , we screened the full-length cDNA clone 
from a cDNA library prepared from pancreatic cancer 
cell lines (see Materials and Methods) and isolated three 
different isoforms (Figure 1C). The three transcriptional 
variants were denoted C16orf74-V1 (GenBank Accession: 
AB115764), -V2 (AB115765) and -V3 (AB115766) and 
consist of 899, 914 and 1518 nucleotides that encode 76, 
20 and 64 amino acids, respectively, as shown in Figure 
1C. The amino acid sequences of these three variants were 
shown in Supplemental Figure 2. 
 The V2 variant has a unique exon 3 (exon 3a) that 
is 22-bp shorter at the 5’ end than exon 3 of V1, resulting 
in a frame shift within exon 3a and an early stop codon. 
The V3 variant lacks exons 1 and 2 and has a unique exon 
3 (exon 3b) that is 834-bp longer at the 5’ end than exon 
3 of V1. Although this variant has the first ATG within 
exon 3b as the initial codon, we did not confirm that 
the protein is translated from this transcript because the 
consensus Kozak sequence was not conserved around 
this ATG sequence. Northern blot analysis with multiple 
normal human tissues and PDAC cell lines revealed that 
the V1 and V2 transcripts but not V3 are up-regulated in 
PDAC cell lines compared with normal tissues (Figure 
1B, Supplemental Figure 1A). Moreover, among 23 
normal organs, the V1 and V2 transcripts were also 
highly expressed in the placenta and weakly in the thyroid 
(Supplemental Figure 1A, 1B), whereas expression of V3 
was relatively high in the lymph node and very low levels 
of expression were observed in the stomach, trachea and 
bone marrow (Supplemental Figure 1A). 
To investigate endogenous C16orf74 expression 
at the protein level, we generated an anti-C16orf74 
polyclonal antibody which can recognize V1 and V3 
proteins, but not V2 protein, and performed Western blot 
analysis using extracts from pancreatic cancer cell lines 
as well as COS7 cells in which C16orf74-V1 protein 
expression vector was exogenously introduced. We 
detected the two major bands in COS7 cells without any 
nonspecific bands and pancreatic cancer cells (Figure 
2A). A few minor additional bands were observed in 
pancreatic cancer cells, but we did not characterize 
further. These minor bands may correspond to another 
isoform(s) that we could not identify by cDNA cloning, 
to modified C16orf74-V1 proteins, or to different proteins 
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that the antibody might have cross-reacted. Moreover, 
the results of western analysis that indicated high level of 
C16orf74-V1 protein in Capan-1, Capan-2, KLM-1, PK-59 
and PK-1 cells, but not in Panc-1, Aspc-1 and Miapaca-2 
cells (Figure 2A), are consistent with the quantitative RT-
PCR (qRT-PCR) results. Hence, we focused on the V1 
protein in subsequent functional analyses. 
To investigate the possible post-translational 
modification of the C16orf74-V1protein, we performed 
a lambda phosphatase assay and observed a band 
Table 1: Clinicopathological characteristics of pancreatic adenocarcinoma patients according to C16orf74 expression
C16orf74 C16orf74
Factor Low expression High expression p value
n = 35 n = 46
Age; median (range) 67 (42-82) 65 (44-89) 0.74
Sex
Male 25 23 0.052
Female 10 23
Tumor size (mm);median (range) 29.5 (10.0-60.0) 35.0 (15.0-73.0) 0.034*
T stage
1-2 1 0 0.25
3-4 34 46
Differentiation





Ph 26 35 0.85
Pb, Pt 9 11
Lymph node metastasis
+ 25 28 0.32
- 10 18
Lymphatic invasion
+ 25 34 0.80
- 10 12
Venous invasion
+ 31 40 0.76
- 4 6
Perineural invasion
+ 32 43 0.73
- 3 3
UICC stage
- 2a 10 18 0.34
2b 24 28
3 - 1 0
CEA (ng/mL); median (range) 4.1 (1.3-34.4) 4.9 (1.1-70.8) 0.11
CA19-9 (U/mL); median (range) 127.8 (1.0-6606) 165.6 (1.0-19238) 0.22
Ph: pancreatic head, Pb: pancreatic body, Pt: pancreatic tail, UICC: Union for International Cancer Control, U/mL: Unit/mL, 
*p < 0.05.
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corresponding to the phosphorylated form (arrow). This 
band disappeared when the cell extracts were incubated 
with lambda phosphatase, but not with protease inhibitor 
(Figure 2B). The Eukaryotic Linear Motif (ELM) 
prediction tool (http://elm.eu.org/index.html) indicated 
that the C16orf74-V1 protein possesses a predicted 
phosphorylation site at threonine 44 (T44) in its middle 
portion (Supplemental Figure 2). Substitution of T44 
to alanine (T44A) abolished the phosphorylated band, 
whereas the T41A substitution did not, indicating that T44 
is a major phosphorylation site of the C16orf74 protein 
(Figure 2C). Moreover, immunocytochemical analysis 
with an anti-C16orf74 antibody revealed that endogenous 
C16orf74 is localized under the plasma membrane 
(Figure 2D). However, although C16orf74 has no 
putative transmembrane domain, it is predicted to possess 
N-myristoylation at glycine 2 (G2) by in silico analysis 
(Supplemental Figure 2). Accordingly, we suspected 
that C16orf74 is anchored to the plasma membrane via 
N-myristoylation at G2, although further analysis of this 
modification of the C16orf74 protein is necessary. 
To further investigate C16orf74 expression in 
PDAC surgical specimens and normal tissue sections, 
we performed immunohistochemical staining with an 
anti-C16orf74 antibody and observed strong staining in 
ductal cancer cells, whereas no staining was observed 
in the corresponding normal pancreatic ductal cells 
(Supplemental Figure 3A). Moreover, consistent with 
the results of the Northern blot analysis, no expression 
was observed in the kidney, liver, heart, and lung 
(Supplemental Figure 3B). 
Correlation between C16orf74 expression pattern 
and PDAC patient prognosis
 To assess the clinicopathological significance 
of C16orf74 overexpression in PDAC, we conducted 
immunohistochemical staining of a tissue microarray 
from 81 PDAC cases that underwent curative surgical 
resection. The relationship between the overall survival 
and the expression level of C16orf74 was evaluated by 
Figure 1: Up-regulated expression of C16orf74 in pancreatic cancer cells and gene structure. A. Semi-quantitative RT-PCR 
analysis in 5 pancreatic cancer cell lines and 12 clinical samples compared with a normal pancreas duct (N). The amount of RNA was 
normalized by tubulin, alpha (TUBA). The positions of C16orf74 PCR primer are shown as dotted lines on Figure 1C. B. Northern blot 
analysis of the expression levels of C16orf74-V1/V2 transcripts in pancreatic cancer cell lines compared with normal tissues. C. Genomic 
structure of the three C16orf74 variants (denoted V1, V2, and V3) spanning an approximately 43-kb region on 16q24, including four exons 
(Ex). Arrows and arrowheads indicate start and stop codons, respectively. The positions of V1/V2-specific and common probes for Northern 
blot analysis are shown as bold lines on V1, V2 and dotted lines on V1,V2,V3, respectively.
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the Kaplan-Meier Method (Figure 3). The C16orf74 
high-expression group (with > 10% positive cancer cells 
in the tissue section) had significantly worse prognosis 
than the C16orf74 low-expression group (with ≤ 10% 
or no positive cancer cells in the tissue section) (median 
survival 10.1 months in the high-expression group vs. 
20.7 months in the low-expression group, p = 0.028). 
The clinicopathological data and C16orf74 expression 
status are shown in Table 1. Multivariate analysis using 
a Cox proportional-hazard model indicated that lymph 
node metastasis status and the C16orf74 expression level 
were independent poor prognostic factors for patients with 
surgically-resected PDAC (2.61; 95%CI (1.51-4.53) and 
2.05; 95%CI (1.25-3.36) at relative risk, respectively). 
Effect of C16orf74 on cell growth and cell invasion
To assess the biological roles of C16orf74 in PDAC 
cell growth, we conducted loss-of-function studies. 
We examined the effect of knockdown of C16orf74 
expression by mammalian vector-based small hairpin 
RNA interference (shRNA) on the cell growth of KLM-
1 and PK-59 cells by colony-formation and MTT assays. 
Semi-quantitative RT-PCR revealed a significant reduction 
of the amount of C16orf74 transcript in both cells lines 
when transfected with the shRNA constructs (si#2 and 
si#3) but not those with the control shRNA (shEGFP) 
(Figure 4A). Consistent with the effect of C16orf74 
knockdown, MTT and colony formation assays clearly 
revealed significant growth inhibition of both cell lines 
(Figure 4B, 4C). To further confirm the growth-promoting 
effects of C16orf74 overexpression, we conducted an 
MTT assay of HEK293T cells transiently transfected with 
C16orf74-expressing plasmids. C16orf74-overexpressing 
cells grew significantly faster than cells transfected with 
mock plasmid, suggesting a growth-promoting effect of 
C16orf74 (Figure 4D). 
 We also performed a Matrigel invasion assay to 
investigate the effect of C16orf74 overexpression on 
Figure 2: Protein expression, modification, and localization of C16orf74 in pancreatic cancer cells. A. Western blot 
analysis of the expression levels of C16orf74 in pancreatic cancer cell lines. Control: Flag-tagged C16orf74-overexpressed diluted cell 
lysate. B. Phosphorylated form (arrow) of endogenous C16orf74 in KLM-1 cells, as examined by Western blot analysis using an anti-
C16orf74 polyclonal antibody. The upper band disappeared when the cell lysate was incubated with lambda phosphatase (PPase (+)). C. 
Phosphorylation at threonine 44 (T44) of C16orf74. Flag-tagged wild type (WT), T41A and T44A mutants of C16orf74 were used to transfect 
COS-7 cells. The phosphorylated form of wild-type C16orf74 (arrow) was disappeared in the T44A mutant. D. Immunocytochemical 
analysis in a pancreatic cancer cell line (PK-1) using the anti-C16orf74 antibody, demonstrating the plasma membrane localization of 
endogenous C16orf74 (Green). DAPI staining is shown in blue.
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cellular invasion ability. The invasion of NIH3T3 cells 
transfected with C16orf74 was significantly enhanced 
compared with the control cells transfected with mock 
plasmid (Figure 4E), suggesting that C16orf74 contributes 
to the highly malignant phenotype of PDAC cells. 
C16orf74-PPP3CA interaction is indispensable for 
invasion
Because the biological functions of C16orf74 are 
unknown, we searched for proteins that interact with 
C16orf74 using the TAP (tandem affinity purification) 
system combined with mass-spectrometry analyses 
(see Materials and Methods). We identified the several 
candidates of C16orf74-binding proteins. Among 
them, the protein phosphatase 3 catalytic subunit alpha 
(PPP3CA), an isoform of Calcineurin A subunit (CnA) 
which is a serine-threonine calcium/calmodulin-dependent 
phosphatase, as a candidate C16orf74-interacting protein 
(Supplemental Figure 4). We focused on PPP3CA as 
a C16orf74-binding partner because C16orf74 protein 
contains a PPP3CA consensus binding sequence (PXIXIT 
motif) by in silico analysis. The exogenous interaction of 
the proteins was confirmed by an immunoprecipitation 
(IP) assay using anti-myc and anti-Flag antibodies 
(Figure 5A), and their endogenous interaction in PK-1 
cells was also confirmed by IP assay using anti-C16orf74 
and anti-PPP3CA antibodies (Figure 5B). Notably, 
PPP3CA bound preferentially to the phosphorylated 
form of C16orf74 (Figure 5A, arrow). We subsequently 
determined whether T44 phosphorylation of C16orf74 is 
Figure 3: Expression of C16orf74 in human PDAC tissues and its correlation with overall survival. A. Immunohistochemical 
staining of C16orf74 in human PDAC tissues and normal pancreatic tissues. Scale bar: 100 μm. B. Kaplan-Meier survival analysis of 
overall survival based on C16orf74 expression in 81 resected PDAC samples. The C16orf74-positive group exhibited significantly lower 
survival rates (p = 0.028). 
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required for the interaction with PPP3CA. Substitution 
of T44 to alanine (T44A) almost completely abolished 
the interaction with PPP3CA (Figure 5C), indicating the 
significance of T44 phosphorylation for interaction of 
these two proteins. Moreover, since C16orf74 possesses 
a PDIIIT sequence (Supplemental Figure 2), a PPP3CA-
binding motif (PxIxIT) conserved in nuclear factor of 
activated T cells (NFATs) transcriptional factor and other 
PPP3CA-binding partners [16-18], we investigated the 
importance of this motif sequence for the C16orf74-
PPP3CA interaction. IP assays demonstrated that a mutant 
in which the PDIIIT sequence within C16orf74 is deleted 
(∆PDIIIT) completely abolished the interaction with 
PPP3CA (Figure 5C), suggesting that C16orf74 binds to 
PPP3CA via PDIIIT, the PxIxIT binding motif, although 
we can not exclude a possibility that the conformational 
change of protein lacking the domain simply diminished 
the interaction. 
To investigate the subcellular localization 
of C16orf74 and PPP3CA in mammalian cells, we 
cotransfected Flag-tagged C16orf74 (wild type or 
∆PDIIIT) and myc-tagged PPP3CA constructs into COS-
7 cells and performed immunocytochemical staining 
analysis. Flag-C16orf74 (wild type: WT) and myc-
PPP3CA colocalized on the same side of cytoplasmic 
membrane of COS-7 cells. By contrast, Flag-C16orf74 
(∆PDIIIT) did not colocalize with myc-PPP3CA and 
was diffusely located in the cytoplasm of COS-7 cells. 
Furthermore, we confirmed that the non-phosphorylated 
form of C16orf74 (the T44A substitutant) did not interact 
with PPP3CA in the IP assay (Figure 5C), and phosphatase 
treatment interrupted the C16orf74-PPP3CA interaction 
(Figure 5E). 
Because PPP3CA is reported to play an important 
role in invasiveness in cancers [19-21], we examined 
whether the C16orf74-PPP3CA interaction is required for 
invasion activity. We performed a Matrigel invasion assay 
using substitutants of C16orf74 that are unable to interact 
with PPP3CA (T44A and ∆PDIIIT). A decrease in invasion 
activity was observed for T44A or ∆PDIIIT compared 
with the wild type (Figure 5F). These findings support the 
hypothesis that the C16orf74-PPP3CA interaction plays a 
critical role in the invasiveness of PDAC cells.
DISCUSSION
In this study, we have focused on C16orf74 
(NM_206967.2), which is frequently over-expressed in 
PDACs but exhibits a restricted expression pattern in 
normal adult tissues. C16orf74 is a functionally unknown 
gene and was identified as Homo sapiens chromosome 
16 open reading frame 74. C16orf74 has been reported as 
part of gene expression profiles such as the inflammation-
associated gene profile [9] and several cancer prognosis-
associated gene profiles [10, 12-15]. mRNA expression of 
C16orf74 has been reported as a factor for good prognosis 
in bladder cancer but controversially it was suggested to 
be associated with lymph node metastasis in tongue cancer 
[12, 15]. 
In this report, we elucidated the detailed structure 
of three transcriptional variants of C16orf74. The V1 
variant was specifically upregulated in PDAC cells, and 
its gene product plays a crucial role in pancreatic cancer 
proliferation and invasion. Immunohistochemical staining 
analysis of the PDAC tissue microarray revealed that 
more than half of PDAC tumors (46/81, 56.8%) had 
high expression of C16orf74 proteins. Multivariate Cox 
proportional hazards analysis demonstrated that C16orf74 
expression level is an independent prognostic factor for 
Table 2: Univariate and multivariate analysis of prognostic factors using the Cox proportional hazards model
Factor
Univariate analysis Multivariate analysis
RR 95% CI p-value RR 95% CI p-value
Age (≤65 / 66<) 1.01 0.63-1.62 0.95
Sex (male / female) 0.85 0.52-1/38 0.51
Tumor size (≤30 / 30<) 1.33 0.82-2.15 0.25
Tumor site (Ph / Pb, Pt) 0.71 0.41-1.24 0.23
Lymph node metastasis (- / +) 2.24 1.31-3.81 0.003* 2.61 1.51-4.53 0.0006*
Lymphatic invasion (- / +) 1.42 0.82-2.45 0.21
Venous invasion (- / +) 2.11 0.95-4.67 0.066
Perineural invasion (- / +) 2.18 0.87-5.48 0.096
C16orf74 expression (low / high) 1.71 1.06-2.77 0.028* 2.05 1.25-3.36 0.004*
RR: relative risk, CI: confidence interval, Ph: pancreatic head, Pb: pancreatic body, Pt: pancreatic tail, *p < 0.05.
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Figure 4: Effect of knockdown of C16orf74 on cancer cell growth. Three C16orf74 siRNA expression vectors (C16orf74-si1, 
-si2, and -si3) and an EGFP siRNA expression vector (siEGFP) as a negative control were transfected into KLM-1 cells (left) and PK-59 
(right). A. The effect of knockdown on the C16orf74 transcript was validated by RT-PCR with ACTB expression as a quantitative control. 
C16orf74-si2 displayed a strong knockdown effect, whereas the effect of C16orf74-si3 was modest. C16orf74-si1 and siEGFP failed to 
exhibit any effect on the level of the C16orf74 transcript. B. Transfection with the C16orf74-si2 vector resulted in a drastic reduction of 
the number of colonies in the colony formation assay compared with cells transfected with siEGFP or C16orf74 -si1. C. Transfection 
with the C16orf74-si2 vector resulted in a drastic reduction of the number of colonies in the MTT assay compared with cells transfected 
with siEGFP (control) or C16orf74 -si1. The number of viable cells was consistent with the colony formation assay. For the KLM-1 cells 
(left), cell viability were 24% reduction in C16orf74-si1 (*** P < 0.0001), 91% reduction in C16orf74-si2 (** P < 0.0001), 54% reduction 
in C16orf74-si3 (*** P < 0.0001). For the PK-59 cells (right), cell viability were 34% reduction in C16orf74-si1 (# P < 0.0001), 62% 
reduction in C16orf74-si2 (## P < 0.0001), 39% reduction in C16orf74-si3 (### P < 0.0001). D. The C16orf74 expression vector or Mock 
vector was transfected into HEK293T cells. The MTT assay revealed enhanced cell growth in C16orf74-over-expressing cells (P = 0.001). 
E. Effect of over-expression of C16orf74 on cell invasion. The C16orf74 expression vector or Mock vector was transfected into NIH3T3 
cells. The Matrigel invasion assay revealed enhanced cell invasion by C16orf74 over-expressing cells (P = 0.03).
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Figure 5: Interaction between C16orf74 and PPP3CA. A. In vitro exogenous association of C16orf74 and PPP3CA. The Flag-
tagged C16orf74 construct or vector alone was cotransfected with a myc-tagged PPP3CA construct into HEK293 cells. Cell lysates were 
immunoprecipitated using mouse anti-Flag antibody (left) or anti-myc antibody (right). Immunoblotting of the immunoprecipitates with 
rabbit anti-Flag or anti-myc antibodies revealed a specific interaction between the phosphorylated form of C16orf74 (arrow) and PPP3CA. 
B. In vitro endogenous association of C16orf74 and PPP3CA from Capan-1 pancreatic cancer cells, which endogenously express high 
levels of both C16orf74 and PPP3CA. Capan-1 cell lysates were immunoprecipitated using anti-C16orf74 antibody (left) or anti- PPP3CA 
antibody (right). Immunoblotting of the immunoprecipitates with anti-C16orf74 antibody or anti-PPP3CA antibodies revealed a specific 
interaction between C16orf74 and PPP3CA. Endogenous PPP3CA interacted with the phosphorylated form of endogenous C16orf74 
(arrow). C. Interactions of wild-type C16orf74 (WT) and mutants of C16orf74 with PPP3CA, as assessed by IP analysis. Expression 
vectors for myc-His-tagged PPP3CA and Flag-tagged C16orf74 constructs were doubly transfected into HEK293T cells. C16orf74 (anti-
Flag) was IP, and the indicated molecules were immunoblotted (IB) in western blot analysis. WT, replacement (T44A; non-phosphorylated 
form of C16orf74) and deletion mutants (∆PDIIIT; deletion mutant of PPP3CA binding motif) were analyzed. PPP3CA bound to wild-type 
C16orf74 but not the non-phosphorylated form of C16orf74 or the deletion mutant of the PPP3CA binding motif. D. Subcellular localization 
of C16orf74 (wild type or ∆PDIIIT) and PPP3CA in mammalian cells. Flag-tagged (green) C16orf74 (wild type or ∆PDIIIT) and myc-
tagged (red) PPP3CA constructs were cotransfected into COS-7 cells and subjected to immunocytochemical staining. Flag-C16orf74 (wild 
type) and myc-PPP3CA colocalized on the under the cytoplasmic membrane of COS-7 cells (yellow), but Flag-C16orf74 (∆PDIIIT) did 
not colocalize with myc-PPP3CA, which was present diffusely in the cytoplasm. E. Interactions of endogenous C16orf74 with PPP3CA as 
assessed by IP analysis. The phosphorylated form (arrow) of endogenous C16orf74 in KLM-1 cells, as examined by western blot analysis 
using an anti-C16orf74 polyclonal antibody. Pre IP (left; non-immunoprecipitated by PPP3CA), the phosphorylated form of C16orf74 
(upper band) disappeared when the cell lysate was incubated with lambda phosphatase (PPase (+)). Immunoprecipitation by PPP3CA 
(right) revealed that the phosphorylated form of C16orf74 (upper band) interacted with PPP3CA, whereas the non- phosphorylated form 
of C16orf74 did not. F. Invasion activity of wild-type C16orf74 (WT) and the two mutants (T44A: non-phosphorylated form of C16orf74; 
and ∆PDIIIT, deletion mutant of the PPP3CA binding motif). The WT-C16orf74 expression vector, T44A-C16orf74 expression vector, 
∆PDIIIT-C16orf74 expression vector, and Mock vector were each transfected into NIH3T3 cells. The Matrigel invasion assay revealed 
an enhanced cell number for WT-C16orf74-over-expressing cells (3.4-fold, *P = 0.013) but not so enhanced for ∆PDIIIT-C16orf74-over-
expressing cells (1.4-fold, **P = 0.017) or T44A-C16orf74-over-expressing cells (2.3-fold,***P = 0.038).
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postoperative survival of PDAC patients. Hence, our data 
suggest that C16orf74 has an oncogenic function, is a 
biomarker for poor prognosis, and could be a promising 
therapeutic target for pancreatic cancer. Our results are in 
contrast to those for bladder cancer, for which C16orf74 
is a good prognostic factor [12]. This discrepancy might 
be due to differences of mRNA expression pattern of each 
variant of C16orf74 in different cancer type, although 
further analysis will be necessary. We also searched 
the somatic mutations and copy number alterations 
in C16orf74 gene in PDACs by COSMIC database 
(Catalogue of somatic mutations in cancer: http://cancer.
sanger.ac.uk/cosmic), but found no somatic mutations and 
copy number alterations in this genes. 
In this report, we demonstrated for first time that the 
C16orf74-PPP3CA interaction via PDIIIT, the PPP3CA-
binding motif (PxIxIT) and T44 phosphorylation is 
potentially indispensable for PDAC invasiveness. PPP3CA 
is reported to interact with NFATs (NFATc1, NFATc2, 
NFATc3 and NFATc4) transcriptional factors, and have a 
crucial role in the regulation of immune response [26], 
and invasiveness of cancer cells [19-21, 27, 28]. It was 
reported that down-regulation of PPP3CA gene expression 
could decrease the proliferation, the cell migration and 
invasion of small-cell lung cancer. In addition, in vivo 
down- or up-regulation of PPP3CA gene expression 
could decrease or increase the bone metastasis [29]. The 
NFATs are regulated at the level of their subcellular-
localization via the action of the Ca2+/calmodulin-
dependent serine/threonine phosphatase calcineurin (Cn) 
[30]. The increase of intracellular Ca2+ level leads to 
activation of Cn, thereby induces nuclear-translocation of 
transcriptional factor NFATs [31, 32]. More importantly, 
PPP3CA-NFATs pathway is reported to be crucial in 
pancreatic cancer growth and invasion [33, 34]. We 
demonstrated here that the inhibition of the interaction 
between C16orf74 and PPP3CA using T44A and ∆PDIIIT 
constructs led to the suppression of the invasiveness of 
cancer cells. Accordingly, these evidences suggest that the 
up-regulation of the PPP3CA pathway via the C16orf74-
PPP3CA interaction under the plasma membrane of PDAC 
cells should lead to constitutive nuclear-translocation 
and transcriptional activation of NFATs, resulting in up-
regulation of cancer-related genes such as c-myc leading 
to enhancement of cell proliferation and invasiveness, 
although further elucidation of mechanism of NFATs 
signaling activation in C16orf74-overexpressing PDAC 
cells will be necessary. Moreover, since C16orf74 is 
reported to be a gene associated with hypoxia [35, 36], 
we examined the involvement of C16orf74 expression in 
Hypoxia by using public genome-wide gene expression 
profiling database, and found that C16orf74 gene is a 
Hypoxia- inducible factor 1(HIF1)-regulated gene [37]. 
Further elucidation of biological roles of C16orf74 as a 
HIF-1 regulated gene in PDAC cells will be necessary. 
In conclusion, our findings clearly demonstrate 
that C16orf74 is overexpressed in the vast of majority 
of human PDAC, and likely plays a significant role in 
pancreatic pancreatic cell growth and invasion through its 
interaction with PPP3CA. We suggest that C16orf74 could 
be a useful prognostic marker for PDAC and any means 
to inhibit C16orf74-PPP3CA complex formation could be 
promising to treat PDAC. 
MATERIALS AND METHODS
Cell lines and clinical materials
Cell lines: The PDAC cell lines Capan-1, Capan-2, 
MIA-Paca2, Panc-1, and Aspc-1, the embryonic kidney 
cell line HEK293, and NIH3T3 were purchased from 
American Type Culture Collection (ATCC, Rockville, 
Maryland). The PDAC cell lines PK-59 and KLM-1 were 
provided by the Cell Resource Center for Biomedical 
Research, Tohoku University (Sendai, Japan). All cells 
were cultured in appropriate media: RPMI-1640 (Sigma, 
St. Louis, MO) for Capan-1, Capan-2, Aspc-1, KLM-1, 
and PK-59 and Dulbecco’s modified Eagle’s medium 
(Invitrogen, Carlsbad, CA) for MIApaca-2, Panc-1, and 
NIH3T3. Each medium was supplemented with 10% fetal 
bovine serum (Cansera) and 1% antibiotic/antimycotic 
solution (Sigma). Cells were maintained at 37°C in an 
atmosphere of humidified air with 5% CO2. Clinical 
samples (pancreatic cancer and normal pancreatic duct) 
were obtained from surgical specimens that were resected 
at Hokkaido University Hospital. Informed consent was 
obtained from patients, and the study was approved by 
the institutional review board of Hokkaido University 
Hospital (ID; 014-0224). Normal tissue sections were 
purchased from Biochain (Hayward, CA, USA). 
Northern blot analysis
Human multiple-tissue Northern blots (Clontech, 
Palo Alto, CA) or a membrane including RNA samples 
from cancer cell lines and normal organs (Clontech) 
were hybridized with a [32P]-dCTP-labeled amplification 
product of C16orf74 prepared by RT-PCR (see below). 
Pre-hybridization, hybridization and washing were 
performed according to the supplier’s recommendations. 
The blots were autoradiographed with intensifying screens 
at -80°C for 10 days. A specific probe for V1 and V2 was 
prepared using exon 1 and 2 of C16orf74, and the V1-3 
common probe was prepared using exon 4 as the template.
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cDNA library screening
We constructed a cDNA library using a 
SuperscriptTM plasmid system with GatewayTM technology 
for cDNA synthesis, a cloning kit (Invitrogen) and 
poly(A)+ RNA obtained from pancreatic cancer cell line 
Capan-1. We screened 3X106 independent clones of this 
library using the same cDNA probes used for Northern 
blot analysis.
Semi-quantitative RT-PCR analysis
The extraction of total RNAs from clinical samples 
of laser-microdissected cells was performed as described 
previously [8]. The amplified RNA or total RNA was 
reverse transcribed to generate single-stranded cDNAs 
using a random primer (Roche) or oligo(dT)16 primer with 
Superscript II reverse transcriptase (Roche). We prepared 
appropriate dilutions of each single-stranded cDNA for 
subsequent PCR amplification by monitoring tubulin, alpha 
3 (TUBA3) as a quantitative control. The primer sequences 
were 5’-CTTGGGTCTGTAACAAAGCATTC-3’ and 
5’-AAGGATTATGAGGAGGTTGGTGT-3’ for TUBA3 
and 5’-GTCCTGAAAGTCAAGCACCTG-3’ and 
5’-GAAGTTCTTGTTGGTGCTTATGG-3’ for C16orf74. 
All reactions involved initial denaturation at 94°C for 2 
min, followed by 22 cycles (for TUBA3) or 28 cycles 
(for C16orf74) of 94°C for 30 s, 58°C for 30 s, and 72°C 
for 1 min on a GeneAmp PCR system 9700 (PE Applied 
Biosystems). 
Preparation of recombinant C16orf74 (rC16orf74)
The full-length C16orf74-V1 cDNA fragment 
was generated by RT-PCR and cloned into pGEX-6P-1 
(Life Technologies). Recombinant GST-tagged protein 
was expressed in Escherichia coli BL21 codonplus 
(Agilent). After induction with 0.2 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) at 25°C, the bacterial pellet 
was suspended in lysis buffer and purified with Glutathione 
Sepharose resin (GE Healthcare) in accordance with the 
manufacturer’s instructions. The GST-C16orf74 fusion 
protein was digested with PreScission Protease for 20 h 
and then further purified by column chromatography using 
a Mono Q HR5/5 column (GE Healthcare) and an ÄKTA 
purifier (GE Healthcare). 
Polyclonal antibody against C16orf74
Polyclonal anti-C16orf74 antibodies were raised 
in rabbits against purified C16orf74 recombinant protein 
(rC16orf74) (Medical and Biological Laboratories, 
Nagoya, Japan). The high-titer antiserum was affinity-
purified using rC16orf74 and a C16orf74-peptide 
(HDEAPVLNDKHLDVPDI) coupled support (Affigel 15; 
BioRad, Hercules, CA, USA). This antibody can recognize 
V1 and V3 of C16orf74 protein, but not V2.
Western blot analysis
The cultured cells were washed twice with PBS and 
harvested in lysis buffer (150 mM NaCl, 1% Triton X-100, 
50 mM Tris-HCl pH 7.4, 1 mM DTT, and 1X complete 
Protease Inhibitor Cocktail (Boehringer)). After the cells 
were homogenized and centrifuged at 10,000xg for 30 
min, the protein concentration of the supernatant was 
standardized by the Bradford assay (Bio-Rad). Proteins 
were separated by 12% SDS-PAGE and immunoblotted 
with antibody. The antibodies used in the western blot 
analysis were rat anti-HA, mouse anti-HA (sc-7392, 
Santa Cruz), anti-Flag-M2, rabbit anti-Flag (F7425, 
SIGMA), mouse anti-beta-actin (A5441, SIGMA), mouse 
anti-PPP3CA (sc-17808, Santa Cruz), and rabbit anti- 
C16orf74 antibodies.
Lambda-phosphatase assay
The lysate of KLM-1 cells was treated with lambda 
protein phosphatase (New England BioLabs) according 
to the manufacturer’s instructions. In the PPP3CA 
interaction assay, the KLM-1 cell lysate was incubated 
with lambda protein phosphatase, immunoprecipitated by 
mouse monoclonal PPP3CA (sc-17808, Santa Cruz) and 
immunoblotted with rabbit polyclonal C16orf74, as in the 
western blot analysis.
Immunochemical staining
Cultured cells were fixed with PBS containing 4% 
paraformaldehyde for 20 min at 4°C and permeabilized 
with PBS containing 0.1% Triton X-100 for 2.5 min at 
room temperature. The cells were blocked with 3% BSA 
in PBS for 1 hr and then incubated with rabbit anti-
C16orf74 or mouse anti-Flag-M2 antibody for 1 hr at 
room temperature, followed by incubation with Alexa488-
conjugated secondary antibody (Molecular Probes). Nuclei 
were counter-stained with DAPI. Fluorescent images were 
obtained by confocal microscopy (Leica).
Paraffin-embedded sections of pancreatic cancer 
and normal tissues were treated with xylene, and antigen 
retrieval was performed by microwaving in antigen-
retrieval buffer (DAKO). Endogenous peroxidase 
activity was blocked by incubation with Peroxidase 
Blocking Reagent (DAKO). Sections were blocked with 
Protein Block Serum-Free (DAKO) for 30 min and then 
incubated with anti-C16orf74 antibody for 30 min at room 
temperature. After washing with PBS, the sections were 
incubated with HRP-conjugated anti-rabbit IgG (DAKO) 
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and color developed with DAB. Finally, the sections were 
counterstained with hematoxylin. Images were obtained 
by a CCD camera attached to a microscope (Olympus).
Tissue microarray
The tissue microarray (TMA) was constructed as 
described previously [38]. PDAC tissue samples were 
obtained from 99 PDACs resected at Hokkaido University 
Hospital between 1999 and 2005. C16orf74-positive was 
defined as stronger cytoplasmic staining of C16orf74 in 
pancreatic cancer cells than in normal pancreas tissue. 
Immunoreactivity was evaluated on a scale considering 
the extent (score- for positive cancer cells ≤10% or score+ 
for positive cancer cells > 10%) of staining. We classified 
the TMA cases into a low-expression group and high-
expression group, as defined by an extent score of - or +, 
respectively, if defined as such by three reviewers (T.N., 
S.S., T.K.). Eighteen patients without information about 
survival and clinicopathological factors were omitted 
from the analysis, and 81 patients were finally subjected 
to the analysis (follow-up term from 2.0 to 156.3 months). 
Informed consent was obtained from patients, and the 
study was approved by the Institutional Review Board 
of Hokkaido University Hospital (No. 014-0221). Patient 
tumor stage was classified according to the tumor-
node-metastasis (TNM) classification of the Union for 
International Cancer Control (UICC) [39].
Gene silencing of C16orf74 in PDAC Cells
 To knockdown the gene expression of C16orf74 in 
PDAC cells, we used a psiU6BX3.0 vector to express a 
short-hairpin RNA against the target gene, as described 
previously [40]. The target sequences for C16orf74 were 
5V- CGACAAGCACCTGGACGTG-3V(C16orf74-si1), 
5V- ATGTGTGTCAGCAGCAGCA-3V (C16orf74-si2), 
5V- GTTGTTTTACAGATACGGA-3V (C16orf74-si3), 
and 5V-GAAGCAGCACGACTTCTTC-3V (for siEGFP 
as a negative control). The human PDAC cell lines 
KLM-1 (5x105 cells per dish) and PK-59 (2x105 cells per 
dish) were plated on 10-cm dishes and transfected with 
psiU6BX vectors including the target sequences for EGFP 
and C16orf74 using Nucleofector (Amaxa Biosystems, 
Cologne, Germany) according to the manufacturer’s 
protocol. Cells were selected in medium containing 500 
µg/mL G418 for 7 days and then harvested to analyze 
the effect of knockdown on C16orf74 expression. The 
primers for these RT-PCR experiments were the same 
as those described above. For the colony formation 
assay, transfectants expressing siRNA were grown for 
7 days in media containing G418. After fixation in 4% 
paraformaldehyde, the transfected cells were stained 
with Giemsa solution to assess colony formation. Cell 
viability was quantified using cell counting kit-8 (Dojindo, 
Kumamoto, Japan). 
Matrigel invasion assay
NIH3T3 cells transfected with the pCAGGS-
C16orf74-Flag vector or empty pCAGGS/ Flag mock 
vector were grown to near confluence in culture medium 
containing 10% FBS. The cells were harvested by 
trypsinization, washed, and finally suspended in serum-
free culture medium at a concentration of 2 × 105 cells/
mL. Before preparing the cell suspension, the dried layer 
of the Matrigel matrix (Becton Dickinson Labware) 
was rehydrated with culture medium for 2 hr at room 
temperature. Culture medium (0.75 mL) containing 10% 
FBS was added to each lower chamber in 24-well Matrigel 
invasion chambers, and 0.5 mL (1 × 105 cells) of cell 
suspension was added to each insert of the upper chamber. 
The inserts were incubated for 22 hr at 37°C. After 
incubation, the chambers were processed; cells invading 
through the Matrigel were fixed and stained by Giemsa 
as directed by the supplier (Becton Dickinson Labware). 
An identical experiment was performed for NIH3T3 cells 
transfected with the pCAGGS-ΔPDIIIT C16orf74-Flag 
vector or pCAGGS- T44A mutant C16orf74-Flag vector. 
Cell proliferation assay
HEK293T cells were plated into a 6-well microtiter 
plate and transiently transfected with pCDNA3.1 Myc-
His-C16orf74 or pcDNA3.1 Myc-His mock control 
expression vector using Fugene 6 transfection reagent 
(Roche) according to the manufacturer’s instructions. 
Seven days after transfection, cell viability was quantified 
using cell counting kit-8 (Dojindo). 
Immunoprecipitation and mass spectrometric 
analysis of C16orf74-associated complexes
To isolate proteins that associated directly with 
C16orf74, we used the TAP system (tandem affinity 
purification system) combined with mass spectrometry 
analysis. The TAP procedure was performed essentially as 
described previously with some modifications [41]. The 
TAP vector expresses an amino-terminal HA-tagged target 
protein with carboxy-terminal TAP tags in mammalian 
cells under the control of a cytomegalovirus promoter. 
The TAP vector with HA-tagged C16orf74 or Mock-HA 
was transiently transfected into Panc-1 cells, followed 
by lysis in lysis buffer [50 mM Tris-HCl (pH 8.0), 150 
mM NaCl, 0.5% NP40, Protease Inhibitor Cocktail Set 
III (Calbiochem, San Diego, CA)]. Equal amounts of 
total proteins were incubated at 4°C for 1 hr with anti-HA 
antibody. Immunocomplexes were incubated with protein 
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G-Sepharose (Zymed Laboratories, South San Francisco, 
CA) for 1 hr and washed with lysis buffer. Coprecipitated 
proteins were separated in a 5% to 20% gradient SDS-
PAGE and stained by silver-staining kits (Wako, Osaka, 
Japan). Bands that differentiated proteins precipitated with 
HA-C16orf74 from those precipitated with HA-Mock 
were excised, digested in gel with trypsin, and analyzed 
for peptide-mass fingerprints using an AXIMA-CFR +6 
mass spectrometer (Shimadzu Corporation, Tsukuba, 
Japan). Peptide masses were searched with 10-ppm mass 
accuracy, and protein database searches were performed 
using the database-fitting program IntelliMarque 
(Shimadz).
Immunoprecipitation and western blotting
Transfected cells were harvested with RIPA buffer 
(150 mM NaCl, 1% NP-40, 50 mM Tris-HCl (pH 8.0), 
0.1% SDS, 0.5% sodium deoxycholate, and 1X protease 
inhibitor cocktail set III (Calbiochem)) 2 days after 
transfection. Immunoprecipitation was performed with 
mouse anti-Myc (9E10, Santa Cruz) antibody or anti-
Flag-M2 (F3165, SIGMA) antibody. The antibodies 
were removed by incubation with protein G Sepharose 
(Zymed/Invitrogen), and the wash step was repeated 5 
times. Proteins were extracted with SDS sample buffer 
and separated by 10-20% gradient SDS-page (Bio-Rad). 
To examine the interaction of Flag-C16orf74 with Myc-
PPP3CA, we analyzed the immune complexes by western 
blotting with rabbit anti-Flag and anti-Myc antibodies. 
To examine the interaction of endogenous C16orf74 with 
endogenous PPP3CA, Capan-1 cells were harvested in 
RIPA buffer, and immunoprecipitation was performed 
with mouse anti-PPP3CA (sc-17808, Santa Cruz) antibody 
or rabbit anti-C16orf74 (immunized with full-length 
recombinant C16orf74 protein) antibodies. Then, we 
collected the antibodies with protein G Sepharose (Zymed/
Invitrogen) and repeated the wash steps 5 times. Proteins 
were extracted with SDS sample buffer and separated by 
10-20% gradient SDS-PAGE (Bio-Rad). We analyzed the 
immune complexes by Western blotting with mouse anti-
PPP3CA (sc-17808, Santa Cruz) antibody, or rabbit anti-
C16orf74 antibodies.
Construction of the expression vector
The entire coding sequence of 
C16orf74 V1 cDNA was amplified by RT-
PCR with the primers C16orf74 V1-forward 
(5’-CCGGAATTCGACATGGGGCTTAAGATGTCC-3’) 
and C16orf74 V1-reverse 
(5’-CCGCTCGAGGGCTTCTGGGTCGATTTCTCC-3’). 
The product was inserted into the EcoRI and XhoI 
sites of pCAGGS to express a Flag-tagged protein 
[42]. The entire coding sequence of PPP3CA 




(reverse) and inserted into the BamHI and XhoI sites of 
pcDNA3.1(+)/Myc-His A (Invitrogen) to express a Myc-
tagged protein.
Statistical analysis
The results are presented as the mean ± SEM of at 
least 3 independent experiments. The data were analyzed 
using the Student’s t-test, Mann-Whitney U test, Fisher’s 
exact test, or χ2 test as appropriate. Overall survival was 
calculated from the date of operation to the date of last 
follow-up or date of patient death. Univariate survival 
analysis was performed according to the Kaplan-Meier 
method, and survival differences were estimated by the 
log-rank test. Multivariate analysis was conducted using 
the Cox proportional hazards regression model. A p-value 
< 0.05 was considered significant, and the confidence 
interval (CI) was determined at the 95% level. All data 
were analyzed using JMP® 10 software. 
ACKNOWLEDGMENTS
The authors thank Ms. Yoshiko Fujisawa for 
technical assistance, and Dr. Keisuke Taniuchi, Dr. 





1. American Cancer Society. Cancer facts & figures 2016. 
Atlanta, Georgia: American Cancer Society; 2016. http://
www.cancer. org/acs/groups/content/@research/documents/
webcontent/ 
2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud 
R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, 
de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-
Akouz F, et al. FOLFIRINOX versus gemcitabine for 
metastatic pancreatic cancer. N Engl J Med. 2011; 
364:1817-25. doi: 10.1056/NEJMoa1011923.
3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante 
J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, 
Harris M, Reni M, Dowden S, et al. Increased survival in 
pancreatic cancer with nab-paclitaxel plus gemcitabine. 
N Engl J Med. 2013; 369: 1691-703. doi: 10.1056/
NEJMoa1304369.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, 
Oncotarget50474www.impactjournals.com/oncotarget
Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, 
Campos D, Lim R, Ding K, et al. Erlotinib plus gemcitabine 
compared with gemcitabine alone in patients with advanced 
pancreatic cancer: a phase III trial of the National Cancer 
Institute of Canada Clinical Trials Group. J Clin Oncol. 
2007; 25: 1960-6. 
5. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P. 
Pancreatic adenocarcinoma: ESMO-ESDO clinical practice 
guidelines for diagnosis, treatment and follow-up. Ann 
Oncol. 2012; 23:vii33-40.
6. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, 
Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly 
E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, et al. 
Gemcitabine plus bevacizumab compared with gemcitabine 
plus placebo in patients with advanced pancreatic cancer: 
phase III trial of the Cancer and Leukemia Group B 
(CALGB 80303). J Clin Oncol. 2010; 28: 3617-22. doi: 
10.1200/JCO.1386.
7. Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, 
Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin 
SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, et 
al. Phase III study comparing gemcitabine plus cetuximab 
versus gemcitabine in patients with advanced pancreatic 
adenocarcinoma: Southwest Oncology Group-directed 
intergroup trial S0205. J Clin Oncol. 2010; 28: 3605-10. 
doi: 10.1200/JCO.7550.
8. Nakamura T, Furukawa Y, Nakagawa H, Tsunoda 
T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, 
Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh 
H, et al. Genome-wide cDNA microarray analysis of gene 
expression profiles in pancreatic cancers using populations 
of tumor cells and normal ductal epithelial cells selected for 
purity by laser microdissection. Oncogene. 2004; 23: 2385-
400.
9. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman 
E, Khalili H, Damle A, Kern M, Furie R, Dupuis J, 
Plenge RM, Coenen MJ, et al. Genome-wide association 
scan identifies candidate polymorphisms associated with 
differential response to anti-TNF treatment in rheumatoid 
arthritis. Mol Med. 2008; 14: 575-81. doi: 10.2119/2008-
00056.
10. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, 
Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, 
Musgrove B, Slevin N, Sloan P, et al. Relation of a hypoxia 
metagene derived from head and neck cancer to prognosis 
of multiple cancers. Cancer Res. 2007; 67: 3441-9.
11. Ebbesen P, Pettersen EO, Gorr TA, Jobst G, Williams K, 
Kieninger J, Wenger RH, Pastorekova S, Dubois L, Lambin 
P, Wouters BG, Van Den Beucken T, Supuran CT, et al. 
Taking advantage of tumor cell adaptations to hypoxia for 
developing new tumor markers and treatment strategies. 
J Enzyme Inhib Med Chem. 2009; 24 Suppl 1:1-39. doi: 
10.1080/14756360902784425.
12. Kim WT, Yun SJ, Park C, Kim IY, Moon SK, Kwon TG, 
Choi YH, Kim WJ. Identification of C16orf74 as a marker 
of progression in primary non-muscle invasive bladder 
cancer. PLoS One. 2010; 5:e15260. doi: 10.1371/journal.
pone.0015260.
13. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim 
MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC. 
Predictive value of progression-related gene classifier in 
primary non-muscle invasive bladder cancer. Mol Cancer. 
2010; 9:3. doi: 10.1186/1476-4598-9-3.
14. Ha YS, Kim JS, Yoon HY, Jeong P, Kim TH, Yun SJ, Lee 
SC, Kim GY, Choi YH, Moon SK, Yi Kim I, Kim WJ. 
Novel combination markers for predicting progression of 
nonmuscle invasive bladder cancer. Int J Cancer. 2012; 131: 
E501-7. doi: 10.1002/ijc.27319 
15. Zhou X, Temam S, Oh M, Pungpravat N, Huang BL, Mao 
L, Wong DT. Global expression-based classification of 
lymph node metastasis and extracapsular spread of oral 
tongue squamous cell carcinoma. Neoplasia. 2006;8:925-
932.
16. Macian F. NFAT proteins: key regulators of T-cell 
development and function. Nat Rev Immunol. 2005; 5: 472-
84.
17. Neal JW, Clipstone NA. A constitutively active NFATc1 
mutant induces a transformed phenotype in 3T3-L1 
fibroblasts. J Biol Chem. 2003; 278: 17246-54.
18. Duque J, Fresno M, Iñiguez MA. Expression and function 
of the nuclear factor of activated T cells in colon carcinoma 
cells: involvement in the regulation of cyclooxygenase-2. J 
Biol Chem. 2005; 280: 8686-93.
19. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, 
Adler G, Gress TM, Ellenrieder V. Overexpression of 
c-Myc in pancreatic cancer caused by ectopic activation 
of NFATc1 and the Ca2+/calcineurin signaling pathway. 
EMBO J. 2006; 25: 3714-24.
20. Wang YL, Wang Y, Tong L, Wei Q. Overexpression of 
calcineurin B subunit (CnB) enhances the oncogenic 
potential of HEK293 cells. Cancer Sci. 2008; 99: 1100-8. 
doi: 10.1111/j.1349-7006 
21. Liu Y, Zhang Y, Min J, Liu LL, Ma NQ, Feng YM, Liu D, 
Wang PZ, Huang DD, Zhuang Y, Zhang HL. Calcineurin 
promotes proliferation, migration, and invasion of small cell 
lung cancer. Tumour Biol. 2010; 31: 199-207. doi: 10.1007/
s13277-010-0031-y.
22. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, 
Cagnoni PJ. Correlation between development of rash and 
efficacy in patients treated with the epidermal growth factor 
receptor tyrosine kinase inhibitor erlotinib in two large 
phase III studies. Clin Cancer Res. 2007; 13: 3913-21.
23. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien 
CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky 
G, Roh JK, Folprecht G, Ruff P, et al. Cetuximab and 
chemotherapy as initial treatment for metastatic colorectal 
cancer. N Engl J Med. 2009; 360: 1408-17. doi: 10.1056/
NEJMoa0805019.
24. Wang P, Fan J, Chen Z, Meng ZQ, Luo JM, Lin JH, 
Oncotarget50475www.impactjournals.com/oncotarget
Zhou ZH, Chen H, Wang K, Xu ZD, Liu LM. Low-level 
expression of Smad7 correlates with lymph node metastasis 
and poor prognosis in patients with pancreatic cancer. Ann 
Surg Oncol. 2009; 16: 826-35. doi: 10.1245/s10434-008-
0284-5.
25. Sho M, Murakami Y, Motoi F, Satoi S, Murakami Y, Motoi 
F, Satoi S, Matsumoto I, Kawai M, Honda G, Uemura K, 
Yanagimoto H, Kurata M, et al. Postoperative prognosis of 
pancreatic cancer with para-aortic lymph node metastasis: 
a multicenter study on 822 patients. J Gastroenterol. 2015; 
50: 694-702. doi: 10.1007/s00535-014-1005-4.
26. Crabtree GR, Olson EN. NFAT signaling: choreographing 
the social lives of cells. Cell. 2002; 109 Suppl:S67-79.
27. Buchholz M, Ellenrieder V. An emerging role for Ca2+/
calcineurin/NFAT signaling in cancerogenesis. Cell Cycle. 
2007; 6: 16-9.
28. Yiu GK, Toker A. NFAT induces breast cancer cell 
invasion by promoting the induction of cyclooxygenase-2. 
J Biol Chem. 2006; 281: 12210-7. 
29. Ma NQ, Liu LL, Min J, Wang JW, Jiang WF, Liu Y, Feng 
YG, Su HC, Feng YM, Zhang HL. The effect of down 
regulation of calcineurin A by lentiviral vector-mediated 
RNAi on the biological behavior of small-cell lung cancer 
and its bone metastasis. Clin Exp Metastasis. 2011; 28:765-
78. doi: 10.1007/s10585-011-9408-6.
30. Loh C, Shaw KT, Carew J, Viola JP, Luo C, Perrino BA, 
Rao A. Calcineurin binds the transcription factor NFAT1 
and reversibly regulates its activity. J Biol Chem. 1996; 
271: 10884-91.
31. Luo C, Shaw KT, Raghavan A, Aramburu J, Garcia-Cozar 
F, Perrino BA, Hogan PG, Rao A. Interaction of calcineurin 
with a domain of the transcription factor NFAT1 that 
controls nuclear import. Proc Natl Acad Sci U S A. 1996; 
93: 8907-12.
32. Shibasaki F, Price ER, Milan D, McKeon F. Role of kinases 
and the phosphatase calcineurin in the nuclear shuttling of 
transcription factor NF-AT4. Nature. 1996; 382: 370-3.
33. König A, Fernandez-Zapico ME, Ellenrieder V. Primers 
on molecular pathways--the NFAT transcription pathway 
in pancreatic cancer. Pancreatology. 2010;10:416-22. doi: 
10.1159/000315035.
34. Köenig A, Linhart T, Schlengemann K, Reutlinger K, 
Wegele J, Adler G, Singh G, Hofmann L, Kunsch S, Büch 
T, Schäfer E, Gress TM, Fernandez-Zapico ME, et al. 
NFAT-induced histone acetylation relay switch promotes 
c-Myc-dependent growth in pancreatic cancer cells. 
Gastroenterology. 2010; 138:1189-99.e1-2. doi: 10.1053/j.
gastro.2009.10.045.
35. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, 
Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, 
Musgrove B, Slevin N, Sloan P, et al. Relation of a hypoxia 
metagene derived from head and neck cancer to prognosis 
of multiple cancers. Cancer Res. 2007; 67: 3441-9.
36. Ebbesen P, Pettersen EO, Gorr TA, Jobst G, Williams K, 
Kieninger J, Wenger RH, Pastorekova S, Dubois L, Lambin 
P, Wouters BG, Van Den Beucken T, Supuran CT, et al. 
Taking advantage of tumor cell adaptations to hypoxia for 
developing new tumor markers and treatment strategies. 
J Enzyme Inhib Med Chem. 2009; 24 Suppl 1:1-39. doi: 
10.1080/14756360902784425.
37. Mimura I, Nangaku M, Kanki Y, Tsutsumi S, Inoue T, 
Kohro T, Yamamoto S, Fujita T, Shimamura T, Suehiro 
J, Taguchi A, Kobayashi M, Tanimura K, et al. Dynamic 
change of chromatin conformation in response to hypoxia 
enhances the expression of GLUT3 (SLC2A3) by 
cooperative interaction of hypoxia-inducible factor 1 and 
KDM3A. Mol Cell Biol. 2012; 32:3018-32. doi: 10.1128/
MCB.06643-11.
38. Tanaka K, Tsuchikawa T, Miyamoto M, Maki T, 
Ichinokawa M, Kubota KC, Shichinohe T, Hirano S, 
Ferrone S, Dosaka-Akita H, Matsuno Y, Kondo S. Down-
regulation of Human Leukocyte Antigen class I heavy chain 
in tumors is associated with a poor prognosis in advanced 
esophageal cancer patients. Int J Oncol. 2012; 40: 965-74. 
doi: 10.3892/ijo.2011.1274.
39. Sobin LH, Gospodarowicz MK, Wittekind C. Wittekind. 
International Union Against Cancer. TNM classification of 
malignant tumours (7th ed.) Wiley-Liss, New York. 2009.
40. Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin 
YM, Nakamura Y. Involvement of the FGF18 gene in 
colorectal carcinogenesis, as a novel downstream target of 
the h-catenin/T-cell factor complex. Cancer Res. 2003; 63: 
6116-20.
41. Ozaki K, Inoue K, Sato H, Iida A, Ohnishi Y, Sekine A, 
Sato H, Odashiro K, Nobuyoshi M, Hori M, Nakamura Y, 
Tanaka T. Functional variation in LGALS2 confers risk 
of myocardial infarction and regulates lymphotoxin-alpha 
secretion in vitro. Nature. 2004; 429: 72-5.
42. Niwa H, Yamamura K, Miyazaki J. Efficient selection 
for high-expression transfectants with a novel eukaryotic 
vector. Gene. 1991; 108: 193-9.
